Nurix Therapeutics Inc

(b) Director and Section 16 Officer Rule 10b5-1 Trading Arrangements

On November 12, 2024, Hans van Houte, Chief Financial Officer of the Company, entered into a prearranged trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (van Houte Plan), providing for the potential sale of up to 162,877 shares of the Company’s common stock, including shares of common stock previously issued to Mr. van Houte pursuant to the exercise of option awards, shares of common stock issuable upon the exercise of option awards, and shares of common stock to be acquired upon the vesting and settlement of restricted stock units (RSUs) granted, each so long as the market price of the Company’s common stock is higher than certain minimum threshold prices specified in the van Houte Plan. A portion of the shares underlying the options are expected to be sold in the market to cover the exercise price and taxes associated with the exercise of the options. The remaining shares underlying the options will be sold in the open market at the times and prices specified in the van Houte Plan. The actual number of shares sold in connection with the vesting and settlement of RSUs will be net of shares mandatorily sold in the open market to cover tax withholding obligations. The first potential sale date under the van Houte Plan is March 3, 2025. The van Houte Plan expires on December 31, 2025, or upon the earlier completion of all authorized transactions thereunder.

No other director or Section 16 officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, during the quarter ended November 30, 2024.